JP2005500347A - 女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与 - Google Patents

女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与 Download PDF

Info

Publication number
JP2005500347A
JP2005500347A JP2003516530A JP2003516530A JP2005500347A JP 2005500347 A JP2005500347 A JP 2005500347A JP 2003516530 A JP2003516530 A JP 2003516530A JP 2003516530 A JP2003516530 A JP 2003516530A JP 2005500347 A JP2005500347 A JP 2005500347A
Authority
JP
Japan
Prior art keywords
testosterone
dihydrotestosterone
pge
agonist
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003516530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500347A5 (enExample
Inventor
レランド エフ． ウィルソン，
ピーター ワイ． タム，
Original Assignee
ヴィヴァス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィヴァス・インコーポレイテッド filed Critical ヴィヴァス・インコーポレイテッド
Publication of JP2005500347A publication Critical patent/JP2005500347A/ja
Publication of JP2005500347A5 publication Critical patent/JP2005500347A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003516530A 2001-07-27 2002-07-26 女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与 Withdrawn JP2005500347A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/919,471 US20030022875A1 (en) 2001-07-27 2001-07-27 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
PCT/US2002/023840 WO2003011300A1 (en) 2001-07-27 2002-07-26 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness

Publications (2)

Publication Number Publication Date
JP2005500347A true JP2005500347A (ja) 2005-01-06
JP2005500347A5 JP2005500347A5 (enExample) 2005-12-22

Family

ID=25442154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003516530A Withdrawn JP2005500347A (ja) 2001-07-27 2002-07-26 女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与

Country Status (5)

Country Link
US (1) US20030022875A1 (enExample)
EP (1) EP1418920A4 (enExample)
JP (1) JP2005500347A (enExample)
CA (1) CA2455711A1 (enExample)
WO (1) WO2003011300A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013121986A (ja) * 2005-04-15 2013-06-20 Clarus Therapeutics Inc 疎水性薬物のドラッグデリバリーシステムとその組成物
JP2013241463A (ja) * 2005-11-11 2013-12-05 Emotional Brain Bv 女性性的機能不全の処置におけるテストステロンを含む薬剤の組み合わせ
JP2014001235A (ja) * 2006-11-03 2014-01-09 Emotional Medical Bv 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US9192669B2 (en) 2004-05-11 2015-11-24 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2016514706A (ja) * 2013-03-15 2016-05-23 リポカイン インコーポレーテッド 経口送達用リポバランス長鎖テストステロンエステル
US9943527B2 (en) 2010-11-30 2018-04-17 Lipocine Inc. High-strength testosterone undecanoate compositions
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
US11433083B2 (en) 2010-11-30 2022-09-06 Lipocine Inc. High-strength testosterone undecanoate compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
US12310978B2 (en) 2015-06-15 2025-05-27 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
ATE356635T1 (de) * 2001-11-15 2007-04-15 Pantarhei Bioscience Bv Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005058342A1 (en) * 2003-12-16 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating ovulation
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
KR20070050081A (ko) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
KR101052436B1 (ko) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
SG155258A1 (en) * 2004-10-20 2009-09-30 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
ITMI20052377A1 (it) * 2005-12-13 2007-06-14 Anna Petroni Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CA2994401A1 (en) * 2014-08-28 2016-03-03 Lipocine Inc. Pharmaceutical composition and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
US3917841A (en) * 1974-06-03 1975-11-04 Nelson Res & Dev Method for treating libido disorders
JP2001520999A (ja) * 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441592B2 (en) 2004-05-11 2019-10-15 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9700566B2 (en) 2004-05-11 2017-07-11 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9192669B2 (en) 2004-05-11 2015-11-24 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2013121986A (ja) * 2005-04-15 2013-06-20 Clarus Therapeutics Inc 疎水性薬物のドラッグデリバリーシステムとその組成物
US11179402B2 (en) 2005-04-15 2021-11-23 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US9333203B2 (en) 2005-11-11 2016-05-10 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US9737548B2 (en) 2005-11-11 2017-08-22 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JP2013241463A (ja) * 2005-11-11 2013-12-05 Emotional Brain Bv 女性性的機能不全の処置におけるテストステロンを含む薬剤の組み合わせ
US9211334B2 (en) 2006-11-03 2015-12-15 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
JP2015157849A (ja) * 2006-11-03 2015-09-03 イービー アイピー ライブリドス ビー．ブイ． 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US9597335B2 (en) 2006-11-03 2017-03-21 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
JP2014001235A (ja) * 2006-11-03 2014-01-09 Emotional Medical Bv 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
JP2017132809A (ja) * 2006-11-03 2017-08-03 イービー アイピー ライブリドス ビー．ブイ． 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
US10314848B2 (en) 2006-11-03 2019-06-11 Eb Ip Lybridos B.V. Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
US10226473B2 (en) 2010-11-30 2019-03-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US11364250B2 (en) 2010-11-30 2022-06-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US9943527B2 (en) 2010-11-30 2018-04-17 Lipocine Inc. High-strength testosterone undecanoate compositions
US11433083B2 (en) 2010-11-30 2022-09-06 Lipocine Inc. High-strength testosterone undecanoate compositions
US10799513B2 (en) 2010-11-30 2020-10-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US10881671B2 (en) 2010-11-30 2021-01-05 Lipocine Inc. High-strength testosterone undecanoate compositions
US10973833B2 (en) 2010-11-30 2021-04-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US9949985B2 (en) 2010-11-30 2018-04-24 Lipocine Inc. High-strength testosterone undecanoate compositions
US11311555B2 (en) 2010-11-30 2022-04-26 Lipocine Inc. High-strength testosterone undecanoate compositions
US11364249B2 (en) 2010-11-30 2022-06-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
JP2016514706A (ja) * 2013-03-15 2016-05-23 リポカイン インコーポレーテッド 経口送達用リポバランス長鎖テストステロンエステル
US12310978B2 (en) 2015-06-15 2025-05-27 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease

Also Published As

Publication number Publication date
EP1418920A4 (en) 2006-10-04
EP1418920A1 (en) 2004-05-19
WO2003011300B1 (en) 2003-04-10
US20030022875A1 (en) 2003-01-30
CA2455711A1 (en) 2003-02-13
WO2003011300A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
JP2005500347A (ja) 女性の性的欲求および反応性を高めるための経口活性アンドロゲン作用薬の随時投与
US7226910B2 (en) Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
JP2005503374A (ja) 女性の性的欲求および性的反応性を高めるためのアンドロゲン作用薬の随時投与
US20050070516A1 (en) As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6294550B1 (en) Treatment of female sexual dysfunction
US5877216A (en) Treatment of female sexual dysfunction
US20040044080A1 (en) Treatment of dyspareunia with topically administered nitroglycerin formulations
US20040014761A1 (en) Treatment of female sexual dysfunction with phosphodiesterase inhibitors
JP5441966B2 (ja) 活性薬の経皮又は経粘膜適用のための使用及び製剤
US6284263B1 (en) Buccal drug administration in the treatment of female sexual dysfunction
CA2604431A1 (en) Method of increasing testosterone and related steroid concentrations in women
JP2005500347A5 (enExample)
AU2002313708A1 (en) As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
AU2002313709A1 (en) As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
CN1997357A (zh) 透皮或透粘膜应用活性剂的用途和制剂

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20051004